Cargando…

First clinical experience with posterior lumbar interbody fusion using a thermal-sprayed silver-containing hydroxyapatite-coated cage

BACKGROUND: To investigate the possibility of silver (Ag)-induced adverse events and the degree of bone fusion in posterior lumbar interbody fusion surgery using an Ag-containing hydroxyapatite (HA) lumbar interbody cage. METHODS: An Ag-HA cage consisting of highly osteoconductive HA interfused with...

Descripción completa

Detalles Bibliográficos
Autores principales: Morimoto, Tadatsugu, Tsukamoto, Masatsugu, Aita, Katsuhiro, Fujita, Nobuyuki, Mawatari, Masaaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10228124/
https://www.ncbi.nlm.nih.gov/pubmed/37254205
http://dx.doi.org/10.1186/s13018-023-03882-7
_version_ 1785050905524043776
author Morimoto, Tadatsugu
Tsukamoto, Masatsugu
Aita, Katsuhiro
Fujita, Nobuyuki
Mawatari, Masaaki
author_facet Morimoto, Tadatsugu
Tsukamoto, Masatsugu
Aita, Katsuhiro
Fujita, Nobuyuki
Mawatari, Masaaki
author_sort Morimoto, Tadatsugu
collection PubMed
description BACKGROUND: To investigate the possibility of silver (Ag)-induced adverse events and the degree of bone fusion in posterior lumbar interbody fusion surgery using an Ag-containing hydroxyapatite (HA) lumbar interbody cage. METHODS: An Ag-HA cage consisting of highly osteoconductive HA interfused with Ag was developed, and we applied it clinically at three university-affiliated hospitals from April 2020 to December 2020. During the 12-month postoperative observation period, Ag-related adverse events, neuropathy, and postoperative complications were investigated as indicators of safety, while clinical improvement and the fusion status were investigated as indicators of efficacy. Clinical improvement was defined as improvement beyond the minimum clinically important difference (MCID) in the numerical rating scale (NRS; 1.6) for low back and lower limb pain and the Oswestry Disability Index (ODI; 12.8). RESULTS: We performed lumbar interbody fusion using an Ag-HA cage for 48 patients (female, n = 25; mean age, 67.5 years). The mean preoperative NRS was 6.4 (standard deviation, 1.9), while the mean preoperative ODI was 44 [12]. No adverse effects (i.e., argyria) were identified during the 12-month observation period. Surgical site infection occurred in one case, although the implant was preserved via immediate debridement. In total, 39 (81%) participants showed clinical improvement beyond MCID for both NRS and ODI. Bone fusion was achieved at 45 levels (88%) at 6 months and 48 levels (91%) at 12 months postoperatively. CONCLUSIONS: The results of this study suggest that Ag-HA cages can be safely used in spinal fusion procedures and have the potential to prevent postoperative infections, prevent deterioration of the quality of life, and result in favorable outcomes. Larger-scale and longer-term follow-up studies will be required to corroborate these conclusions. Trial registration UMIN 000039964 (date: April 01, 2020).
format Online
Article
Text
id pubmed-10228124
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-102281242023-05-31 First clinical experience with posterior lumbar interbody fusion using a thermal-sprayed silver-containing hydroxyapatite-coated cage Morimoto, Tadatsugu Tsukamoto, Masatsugu Aita, Katsuhiro Fujita, Nobuyuki Mawatari, Masaaki J Orthop Surg Res Research Article BACKGROUND: To investigate the possibility of silver (Ag)-induced adverse events and the degree of bone fusion in posterior lumbar interbody fusion surgery using an Ag-containing hydroxyapatite (HA) lumbar interbody cage. METHODS: An Ag-HA cage consisting of highly osteoconductive HA interfused with Ag was developed, and we applied it clinically at three university-affiliated hospitals from April 2020 to December 2020. During the 12-month postoperative observation period, Ag-related adverse events, neuropathy, and postoperative complications were investigated as indicators of safety, while clinical improvement and the fusion status were investigated as indicators of efficacy. Clinical improvement was defined as improvement beyond the minimum clinically important difference (MCID) in the numerical rating scale (NRS; 1.6) for low back and lower limb pain and the Oswestry Disability Index (ODI; 12.8). RESULTS: We performed lumbar interbody fusion using an Ag-HA cage for 48 patients (female, n = 25; mean age, 67.5 years). The mean preoperative NRS was 6.4 (standard deviation, 1.9), while the mean preoperative ODI was 44 [12]. No adverse effects (i.e., argyria) were identified during the 12-month observation period. Surgical site infection occurred in one case, although the implant was preserved via immediate debridement. In total, 39 (81%) participants showed clinical improvement beyond MCID for both NRS and ODI. Bone fusion was achieved at 45 levels (88%) at 6 months and 48 levels (91%) at 12 months postoperatively. CONCLUSIONS: The results of this study suggest that Ag-HA cages can be safely used in spinal fusion procedures and have the potential to prevent postoperative infections, prevent deterioration of the quality of life, and result in favorable outcomes. Larger-scale and longer-term follow-up studies will be required to corroborate these conclusions. Trial registration UMIN 000039964 (date: April 01, 2020). BioMed Central 2023-05-30 /pmc/articles/PMC10228124/ /pubmed/37254205 http://dx.doi.org/10.1186/s13018-023-03882-7 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Morimoto, Tadatsugu
Tsukamoto, Masatsugu
Aita, Katsuhiro
Fujita, Nobuyuki
Mawatari, Masaaki
First clinical experience with posterior lumbar interbody fusion using a thermal-sprayed silver-containing hydroxyapatite-coated cage
title First clinical experience with posterior lumbar interbody fusion using a thermal-sprayed silver-containing hydroxyapatite-coated cage
title_full First clinical experience with posterior lumbar interbody fusion using a thermal-sprayed silver-containing hydroxyapatite-coated cage
title_fullStr First clinical experience with posterior lumbar interbody fusion using a thermal-sprayed silver-containing hydroxyapatite-coated cage
title_full_unstemmed First clinical experience with posterior lumbar interbody fusion using a thermal-sprayed silver-containing hydroxyapatite-coated cage
title_short First clinical experience with posterior lumbar interbody fusion using a thermal-sprayed silver-containing hydroxyapatite-coated cage
title_sort first clinical experience with posterior lumbar interbody fusion using a thermal-sprayed silver-containing hydroxyapatite-coated cage
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10228124/
https://www.ncbi.nlm.nih.gov/pubmed/37254205
http://dx.doi.org/10.1186/s13018-023-03882-7
work_keys_str_mv AT morimototadatsugu firstclinicalexperiencewithposteriorlumbarinterbodyfusionusingathermalsprayedsilvercontaininghydroxyapatitecoatedcage
AT tsukamotomasatsugu firstclinicalexperiencewithposteriorlumbarinterbodyfusionusingathermalsprayedsilvercontaininghydroxyapatitecoatedcage
AT aitakatsuhiro firstclinicalexperiencewithposteriorlumbarinterbodyfusionusingathermalsprayedsilvercontaininghydroxyapatitecoatedcage
AT fujitanobuyuki firstclinicalexperiencewithposteriorlumbarinterbodyfusionusingathermalsprayedsilvercontaininghydroxyapatitecoatedcage
AT mawatarimasaaki firstclinicalexperiencewithposteriorlumbarinterbodyfusionusingathermalsprayedsilvercontaininghydroxyapatitecoatedcage